A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Aliskiren; Furosemide
- Indications Essential hypertension; Heart failure
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 03 May 2012 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2011 Lithuania added as study country